

Cost Recovery Models and Other Economic Issues Involved in the Implementation of the *NCI Best Practices*

Jim Vaught, NCI OBBR
Lisa B. Miranda, University of Pennsylvania
Bell Harbor International Conference Center
January 28, 2008



Background and Overview

Jim Vaught, NCI OBBR





Background

OBBR Office of Biorepositories and Biospecimen Research

OBBR is exploring several economic issues based on public comments and other input:

- Understanding the overall economic value of biospecimen resources that are accessible to the research community
- Supporting the NCI Leadership in considering approaches to control biospecimen resource costs during a period of NIH budget limitations
- Understanding additional costs associated with implementing the NCI Best Practices
 - Exploring different cost recovery models for supporting biospecimen resources (Lisa Miranda's presentation)



Overall Economic Value of Biospecimen Resources*



- Biological Resource Centers (BRCs) amplify the impact of scientific progress by enabling future generations to build on past discoveries
- BRCs fulfill several important functions, including:
 - Authenticating materials to ensure quality
 - Preserving materials over long periods of time that may have future value
 - Providing Access to materials for the research community
 - Creating Economies of Scale for larger biospecimen resources
- However, maintaining BRCs may be challenging and costly for individual institutions


*Jeffrey L. Furman and Scott Stern, "Climbing Atop the Shoulders of Giants: The Impact of Institutions on Cumulative Research," NBER Working Paper 12523, September 2006.



Cost Recovery for Biospecimen Resources



- Cost recovery provides a mechanism for individual institutions to work with the NCI to maintain valuable biospecimen resources
- Importance of not exceeding cost recovery in developing user fees
- Possible effects of cost recovery on biospecimen access for future generations of researchers
- Challenge of defining cost recovery for different biospecimen resource and funding models



Biobanking Cost Recovery

Lisa B. Miranda, University of Pennsylvania
Technical Director, Tumor Tissue and Biospecimen Bank (TTAB)
University of Pennsylvania





Talk Objectives



Brief Overview: Biospecimen Resource Economic Issues

Brief Overview: Tumor Tissue and Biospecimen Bank

Brief Tutorial

oIntroduction to Cost Recovery

oElucidate TTAB Cost Recovery Pathway

oBrief Highlight of TTAB Cost Recovery Model

oTTAB Cost Analysis 12 Step Walkthrough

oReview Strategies For User Fee Implementation







Brief Overview: TTAB

OBBR Office of Biorepositories and Biospecimen Research



Tumor Tissue and Biospecimen Bank

TTAB Logo Graphics By Federico A. Valdivieso



TTAB's Mission



NEW UPENN SOM CORE Facility & Service Center

➤ Sponsors: Pathology & Abramson Cancer Center

MISSION

- ➤ Create Extensive, Robust Biospecimen & Data Repository
- Centralize Resources: Physical & Virtual Biobank
- ➤ Promote Internal & External Collaborations
- ➤ Harmonize University Biospecimen Banking efforts
- ➤ Standardize Data Collection & Annotation





TTAB Services



Types of Services

oBiospecimen Collection & Banking Support

oTechnical Support

oConsultation & Feasibility Review

oProject Development & Management

oCollection Inventory Management

oPathology Case Review & Annotation

oQuality Management

oTraining & Education

oHistology Services







TTAB Users



3 Types of Users

oPrivate PI Collections

oClinical Trial OR Bench Researcher

oLymphoma, Myeloma, Breast, GU, Lung, Etc...

oDepartmental Biobanks

oENT, GYN

oVirtual Bank For External Institutions

oUPITT & CDC- MVB Project



Introduction To Cost Recovery

Office of Biorepositories

oWhat Does Fee For Service Really Mean? oWhat Does It Take To Be Revenue Neutral? oPro's & Con's of Cost Recovery oHow Implementation of Cost Recovery Can Support NCI Best **Practices**











Fee For Service Model



Most Common Model For Nonprofits

Recouping ALL Costs

oDirect

oOverhead

Mechanism:

Fee for Service Social Enterprise Model

(Kim Alter, 2004)


Pays For Expenses

oSalary Support (Labor & Benefits)

oCapital Deprecation

oService Contracts

oSupplies & Consumables







Revenue Neutrality



▶Biospecimen Resource Fiscal Year Budget Goal







Cost Recovery: It's Good For You



Invaluable Business Tool For Biorepository

oEstablish Real Costs

oDevelop User Fees

oBudgetary Planning

oRevenue Projections & Predictions

oResource Planning

oEconomic Justification

oGrant Planning

oFinancial Proposals


oFinancial Evaluations & Reporting





Cost Recovery: Putting the Pieces Together







The Path To Cost Recovery Is Often Not Clear



MANY roads lead to the Path, but basically there are only two: reason and practice.

Bodhidharma





TTAB Cost Recovery Pathway

OBBR Office of Biorepositories and Biospecimen Research

Existing Biobank

Defined
Metrics for Conducted
Cost Analysis

Determined Service Types



Explored User Fee Issues



Developed User Fees



Developed Quotes for Service





Compared Fees

NEW Biobank



Implemented Billing



The Dreaded Cost Analysis



Curiosity begins as an act of tearing to piece or analysis **Samuel Alexander**

If you don't have time to do it right, when will you have time to do it over?

John Wooden










o User Fee Elements Include:

- o Labor
 - o Direct
 - o General & Administrative
- o Direct Materials
- o General Laboratory Supplies Fees



o Service Contract Fees







Implementation Of Cost Recovery: Billing To Recoup Costs

OBBR Office of Biorepositories and Biospecimen Research

Setting Up Your Billing oDEVELOP

oPricing Structure

oTTAB Examples

oA Few Policies

oQuotes

oUsers

oProjects

o **DESIGN** Deliverable Document

o **DRAFT** Invoices







Why Effective Reporting Is Essential: True Knowledge Is A Powerful Thing



One cannot have economic growth without security. **John Bruton**

The art of economics consists in looking not merely at the immediate but at the longer effects of any act or policy; it consists in tracing the consequences of that policy not merely for one group but for all groups.

Henry Hazlitt





Fiscal Accountability Increased Self Reliance Sustainable Development

Lisa B Miranda

Financial Empowerment



Acknowledgements



Rosemarie Flynn, Assistant Director, Resource Planning & Analysis School of Medicine, University of Pennsylvania.

Provided Initial SOM Cost Analysis Template









CONTACT

Lisa B. Miranda

Technical Director, TTAB

Tumor Tissue and Biospecimen Bank, University of Pennsylvania

Address: Department of Pathology and Laboratory Medicine

Division of Anatomic Pathology

6.025 Founders Pavilion, 3400 Spruce Street

Philadelphia, Pennsylvania. 19104-4283

Phone: 215-615-4744 (*Voicemail option*)

Pager: 215-308-7439 (*Text option*)

Fax: 215-349-5910

Email: mirandal@uphs.upenn.edu

TTAB Website:

www.med.upenn.edu/bncrc/tumor/index.shtml?tumor





Economic and Cost Recovery Issues Discussion



Biospecimen Resources... We **NEED** TO TALK

AND We ALL Have Issues These Are Just A Few...





This Talk Covered Some



How Do You

- o Create A Culture To Support A Fee For Service Approach?
- o Use Cost Recovery To Engage Collaborators/End Users?

How Can You Use Cost Recovery To

- o Support Resource Planning & Aid Resource Growth?
- o Aid Financial & Executive Reporting?

What Are Some Cost Recovery "Best Practice" Tips?

What Are Key Strategies To Promote Adherence?

How Can Cost Recovery

- o Support NCI Best Practices?
- o Promote Data Sharing?
- o Aid Implementation Of Ca tissue Tools & Offset Costs In Adoption?





BUT...Let's Talk Further A Few Things to Chew On



What funding models exist for various biospecimen resources?

o How do they vary among commercial, academic, Government resources?

Is it possible to fully recover costs?

o Is it desirable to fully recover costs? Will recovery of costs affect access?

Will there be additional costs associated with implementing the NCI Best Practices? For informatics, equipment, QA/QC, personnel?

How will the costs to implement NCI's best practices differ in a small biorepository (1 or a few freezers) versus a large facility?



AND...Let's Talk Even Further BECAUSE...*YOUR Expertise Is PRICELESS*



Is it advantageous, from an operational and/or economic point of view, to consolidate biospecimen resources into larger centralized facilities?

o Would a central resource be accepted in your organization?

Is it possible to quantify the economic impact of a biospecimen resource?

o Few studies have addressed this.

Are there newer technologies available that can reduce costs now or in the near future?

Other issues based on your experience?



Cost Recovery: Do It Yourself



Your Mother WAS Right

Try It, You'll Like It





AND... Cost Recovery Is SO MUCH MORE



Cost Recovery Can Aid Evaluation Of 3 *Critical* NCI Questions:

How effectively has the resource performed? What impact has the resource had on research? Is there a continuing need for the resource?





Say It All With Numbers



Cost Recovery Can Demonstrate Financial *Performance*Of The Biospecimen Resource

Financial *Performance* Measures Include:

\$\$ worth of specimens the resource has provided to researchers
\$\$\$ value of projects & researchers supported with specimens/services from the resource
\$\$\$\$ value of different specimen types that the resource has provided
\$\$\$\$ value of difficult to obtain specimens made available to researchers by the resource
Funds recouped from Collections/Distributions/Biorepository Services
Funds recouped from repeat requests
Grant Funding/New projects funded from Biospecimen Resource related publications
Cost efficiency reporting (\$\$\$ Saved to Users)

Per Specimen Savings





What's YOUR Impact?



Cost Recovery Can Demonstrate Financial IMPACT Of A Biospecimen Resource

Financial *Impact* Measures Include:

The financial value of published studies using resource specimens
The financial impact on your Institution from resource-related papers
Determination of Cost per critical research finding.
The financial value from the Biospecimen Resource's contribution towards:

FDA approval of a medical device
Development of useful technologies
Development of useful research techniques
Financial Feedback from users:
Impact of the resource on their research





Everyone Wants To Be Needed



Cost Recovery Can Demonstrate *Continuing Need* To Stakeholders AND Aid Resource Planning

Key Continuing Need Evaluation Questions include:

Is the resource meeting its financial objectives?

Is the Use Cost Effective?

Is the Resource Financially Viable OR promoting sustainable development?

Is the Value of specimens (and data) being provided (collected) worth the cost of running the Facility?

What level of facilitation of scientific progress is necessary to support cost of operations?

Has the resource improved financial issues regarding access to specimens for PI's?

Evaluation of Financial issues related to duplication of effort

Are PI based banks competing with OR impeding funding for central biospecimen resource?

Is the resource still needed?

Financial comparison of alternative specimen sources

Does the resource still need NCI support or can it support itself?

